SMMT 8-K: Fda rejection
The FDA
Filed with the SEC on · accession 0001599298-26-000092
SMMT filed a 8-K (current report) with the SEC on Nov 16, 2026. The FDA issued a Complete Response Letter to Summit Therapeutics regarding its BLA for ivonescimab in combination with platinum-containing chemotherapy for previously treated EGFR-mutant non-small cell lung cancer.
Summary of the filing
The FDA issued a Complete Response Letter to Summit Therapeutics regarding its BLA for ivonescimab in combination with platinum-containing chemotherapy for previously treated EGFR-mutant non-small cell lung cancer. The FDA determined that substantial evidence of effectiveness was not established absent a statistically significant overall survival benefit, and the BLA cannot be approved in its present form.
Key details
✦ Ask GOAX AI about this filing — what it means for SMMT, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SMMT?
Click hereFrequently asked questions
What did SMMT file with the SEC on Nov 16, 2026?
SMMT filed a 8-K (Fda rejection). The FDA issued a Complete Response Letter to Summit Therapeutics regarding its BLA for ivonescimab in combination with platinum-containing chemotherapy for previously treated EGFR-mutant non-small cell lung cancer. The FDA determined that substantial evidence of effectiveness was not established absent a statistically significant overall survival benefit, and the BLA cannot be approved in its present form.
What does a fda rejection mean for SMMT stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other SMMT SEC filings
- 8-K · SEC filingNov 4, 2026
- 10-Q · SEC filingNov 4, 2026
- 8-K · Shelf registrationNov 4, 2026
- DEF 14A · SEC filingOct 19, 2026
- 8-K · Material agreementSep 29, 2026
- 8-K · Fda approvalSep 15, 2026
- 8-K · Fda approvalSep 14, 2026
- 8-K · Fda approvalSep 3, 2026
- 8-K · Fda approvalAug 26, 2026
- 8-K · Fda approvalAug 5, 2026
Get alerts when SMMT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days